Cardiovascular risk according to add-on therapy in patients with type 2 diabetes

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Mr David Thein Aagaard

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

8 More presentations in this session

Presentation thumbnail

Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events

Doctor M. Husain (Toronto, CA)

Abstract Slides

Presentation thumbnail

Vascular endothelial growth factor-C and mortality in patients with diabetes and suspected coronary artery disease: from the ANOX study

Doctor T. Unoki (Kumamoto, JP)

Presentation thumbnail

Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a propensity score-matched study

Professor B. Yan (Hong Kong, CN)

Abstract Slides

Presentation thumbnail

The combined treatment with glucagon like peptide-1 analogues and sodium-glucose co-transporter 2 causes a greater improvement of arterial stiffness than each treatment alone in type 2 diabetes .

Doctor I. Ikonomidis (Athens, GR)

Abstract Slides

Presentation thumbnail

Lentiviral transfer of interleukin 4 gene to 3T3-L1 adipocytes prevents development of lipid-induced insulin resistance

Ms S. Michurina (Pavlovo, RU)

Access the full session

Session thumbnail

Poster Session 3 - Diabetes, adiposity and metabolic syndrome

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

Making personalised prevention everyone's business

Congress Presentation

Saving hearts, extending lives: the impact of risk prevention on lifetime estimates in Germany

Congress Presentation

Cardiovascular prevention in older adults

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources